FindTrial
Sign In

The placebo

DRUG5 trials

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine, Jiangsu HengRui Medicine Co., Ltd., Beijing Tiantan Hospital, Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital of Chongqing Medical University

Conditions

Chemotherapy EffectCognitive ImpairmentIntracranial Hemorrhage, HypertensiveLung Cancer Squamous CellLung Cancer Stage IVMetabolic Syndrome (MetS)PD-1 AntibodyRespiratory Failure

Phase 3

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
NCT03668496
Jiangsu HengRui Medicine Co., Ltd.Chemotherapy Effect, Lung Cancer Squamous Cell, Lung Cancer Stage IV +1
Start: 2018-11-09End: 2021-12-31Updated: 2021-03-15

Unknown Phase

An fMRI Study of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction
NCT02752867
Dongfang Hospital Beijing University of Chinese MedicineCognitive Impairment
Start: 2016-12-31End: 2019-11-30Target: 40Updated: 2019-02-26
Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19
NCT05697016
Beijing Tiantan HospitalRespiratory Failure, Respiratory Infection Virus
Start: 2023-01-31End: 2024-01-31Target: 238Updated: 2023-01-25
Yiqi Huayu Jiedu Therapy for Non-Surgical Supratentorial Hypertensive Intracerebral Hemorrhage
Not yet recruitingNCT07580235
Guangzhou University of Traditional Chinese MedicineIntracranial Hemorrhage, Hypertensive
Start: 2026-08-01End: 2030-02-01Target: 902Updated: 2026-05-12
Preoperative Oral Carbohydrate Loading and Gastrointestinal Recovery After Bariatric Surgery in Metabolic Syndrome
Not yet recruitingNCT07822763
First Affiliated Hospital of Chongqing Medical UniversityMetabolic Syndrome (MetS)
Start: 2026-09-30End: 2027-01-01Target: 208Updated: 2026-09-17

Related Papers

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
2022-01-0339 citations
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
2021-12-16230 citations
Antibodies to watch in 2020.
2020-01-01328 citations